[EN] MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS [FR] COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DE LA MÉLANOCORTINE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION EN MÉDECINE HUMAINE ET EN COSMÉTIQUE
[EN] MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS [FR] COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DE LA MÉLANOCORTINE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION EN MÉDECINE HUMAINE ET EN COSMÉTIQUE
[EN] MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE MÉLANOCORTINE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION EN MÉDECINE HUMAINE ET EN COSMÉTIQUE
申请人:GALDERMA RES & DEV
公开号:WO2010052255A1
公开(公告)日:2010-05-14
The present invention relates to novel melanocortin receptor modulators corresponding to the general formula (I) to compositions containing them, to the process for preparing them and to their use in pharmaceutical or cosmetic compositions.
MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS
申请人:GALDERMA RESEARCH & DEVELOPMENT
公开号:US20150329522A1
公开(公告)日:2015-11-19
The present invention relates to novel melanocortin receptor antagonist compounds corresponding to the general formula (I) below:
to compositions containing them, to the process for preparing them and to their use in pharmaceutical or cosmetic compositions.
MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS
申请人:Galderma Research & Development
公开号:EP2352728B1
公开(公告)日:2014-05-21
US8962846B2
申请人:——
公开号:US8962846B2
公开(公告)日:2015-02-24
[EN] METHOD FOR TREATMENT OF XERODERMA PIGMENTOSUM<br/>[FR] PROCÉDÉ POUR LE TRAITEMENT DU XERODERMA PIGMENTOSUM (ÉPITHÉLIOMATOSE PIGMENTAIRE)
申请人:GALDERMA RES & DEV
公开号:WO2012131090A1
公开(公告)日:2012-10-04
This invention relates to a method of treating xeroderma pigmentosum and related symptoms in patients by administering a MC1R before or after exposing them to visible light.